Gunen Hakan, Mirici Arzu, Meral Mehmet, Akgün Metin
Turgut Ozal Research Center, Department of Pulmonary and Sleep Medicine, Inonu University, Malatya 44069, Turkey.
Curr Opin Pulm Med. 2009 Mar;15(2):133-7. doi: 10.1097/MCP.0b013e32832185da.
Systemic corticosteroids are strongly recommended in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD). As COPD patients are usually elderly and are relatively immobile, side effects of systemic corticosteroids frequently outweigh their beneficial effects. On the contrary, nebulized corticosteroid solutions have a negligible systemic side-effect profile. In this review, as an alternative to systemic corticosteroids, the place of nebulized corticosteroids in exacerbation periods of COPD was summarized.
The number of trials in the literature is increasing. Regarding the available data, high dose nebulized budesonide was found as effective as systemic corticosteroids in exacerbations of COPD. The side-effect profile, blood glucose level in particular, is better for nebulized budesonide.
Findings from recent studies are giving a positive impression on the role of high dose nebulized budesonide in exacerbations of COPD. However, larger and statistically high powered trials testing different types of nebulized corticosteroid solutions with varying dosages are still lacking. Before recommending the routine use of nebulized corticosteroids in exacerbations, present findings need to be confirmed with further studies of high quality.
在慢性阻塞性肺疾病(COPD)急性加重期的治疗中,强烈推荐使用全身性糖皮质激素。由于COPD患者通常年事已高且活动相对较少,全身性糖皮质激素的副作用常常超过其有益作用。相反,雾化吸入糖皮质激素溶液的全身副作用可忽略不计。在本综述中,总结了雾化吸入糖皮质激素在COPD急性加重期作为全身性糖皮质激素替代药物的地位。
文献中的试验数量在增加。根据现有数据,发现高剂量雾化吸入布地奈德在COPD急性加重期与全身性糖皮质激素一样有效。雾化吸入布地奈德的副作用,尤其是血糖水平,情况更好。
近期研究结果对高剂量雾化吸入布地奈德在COPD急性加重期的作用给出了积极印象。然而,仍缺乏针对不同类型、不同剂量雾化吸入糖皮质激素溶液进行的规模更大且具有统计学效力的试验。在推荐将雾化吸入糖皮质激素常规用于急性加重期之前,目前的研究结果需要通过进一步高质量研究加以证实。